Bristol-Myers Squibb pleads guilty to lying about Plavix deal

Share this article:

The US Dept. of Justice (DOJ) Wednesday said that Bristol-Myers Squibb (BMS) has entered guilty pleas to two counts of making false statements to a government agency and will pay the maximum $1 million criminal fine for lying about its Plavix deal with Canadian generics drugmaker Apotex.
The pleas had been expected and bring to a close the DOJ’s investigation into the botched pact last year between the drug makers.
Apotex had sued to have Plavix's patents declared invalid in order to release a generic version of the blockbuster blood-thinner. The case was heard in January, with a decision still pending.
According to the DOJ, BMS was required to have any patent-settlement agreements reviewed beforehand by the FTC, according to the terms of a previous settlement reached between the drugmaker and federal authorities in a separate investigation.
“The FTC warned BMS that it would not approve a settlement of the Plavix litigation if BMS agreed not to launch its own generic version of Plavix that would compete against Apotex for generic sales,” the DOJ said in a statement. “After nevertheless entering into such an agreement, BMS concealed it from and then lied about its existence to the FTC," the DOJ added.
BMS markets Plavix, which had 2005 sales of $5.9 billion, with French drugmaker Sanofi-Aventis.
Last year, BMS CEO Peter Dolan was dismissed by the company’s board of directors after New York State and federal authorities questioned the company's dealings with Apotex over Plavix. Board member James Cornelius, who formerly headed Guidant Corporation, was named CEO earlier this year.

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Channel


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...